Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire • 09/04/24
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 08/13/24
Kezar Life Sciences to Participate in the Jefferies Global Healthcare ConferenceBusiness Wire • 05/29/24
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 05/09/24
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdateBusiness Wire • 03/14/24
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care ConferenceBusiness Wire • 02/28/24
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisBusiness Wire • 02/26/24
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)PRNewsWire • 12/04/23
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx ConferenceBusiness Wire • 11/21/23
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateBusiness Wire • 11/13/23
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive OfficerBusiness Wire • 10/03/23
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million AgreementSeeking Alpha • 09/25/23
Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast AsiaBusiness Wire • 09/20/23
Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)Benzinga • 08/21/23
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business UpdateBusiness Wire • 08/10/23